D-0576-2020 Class II Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-0576-2020 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Dec 2, 2019 and is designated Class II. Reason for recall: Presence of Foreign Substance: Presence of a foreign object in a single tablet. The recall status is terminated (terminated Oct 14, 2021). Affected quantity: 1,824 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 18, 2019
Initiation Date
Dec 2, 2019
Termination Date
Oct 14, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,824 bottles

Product description

Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.

Reason for recall

Presence of Foreign Substance: Presence of a foreign object in a single tablet.

Distribution pattern

Nationwide in the USA.

Code information

Lot #: NT119005A, Exp 07/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0576-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0576-2020. Report a data issue: hello@regdatalab.com.